Literature DB >> 16741123

Onset and progression in inherited ALS determined by motor neurons and microglia.

Séverine Boillée1, Koji Yamanaka, Christian S Lobsiger, Neal G Copeland, Nancy A Jenkins, George Kassiotis, George Kollias, Don W Cleveland.   

Abstract

Dominant mutations in superoxide dismutase cause amyotrophic lateral sclerosis (ALS), a progressive paralytic disease characterized by loss of motor neurons. With the use of mice carrying a deletable mutant gene, expression within motor neurons was shown to be a primary determinant of disease onset and of an early phase of disease progression. Diminishing the mutant levels in microglia had little effect on the early disease phase but sharply slowed later disease progression. Onset and progression thus represent distinct disease phases defined by mutant action within different cell types to generate non-cell-autonomous killing of motor neurons; these findings validate therapies, including cell replacement, targeted to the non-neuronal cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741123     DOI: 10.1126/science.1123511

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  654 in total

Review 1.  Inhibitory synaptic regulation of motoneurons: a new target of disease mechanisms in amyotrophic lateral sclerosis.

Authors:  Lee J Martin; Qing Chang
Journal:  Mol Neurobiol       Date:  2011-11-10       Impact factor: 5.590

2.  Increased axonal mitochondrial mobility does not slow amyotrophic lateral sclerosis (ALS)-like disease in mutant SOD1 mice.

Authors:  Yi-Bing Zhu; Zu-Hang Sheng
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 3.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

4.  D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis.

Authors:  Jumpei Sasabe; Tomohiro Chiba; Marina Yamada; Koichi Okamoto; Ikuo Nishimoto; Masaaki Matsuoka; Sadakazu Aiso
Journal:  EMBO J       Date:  2007-08-30       Impact factor: 11.598

5.  Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.

Authors:  Andrea Crotti; Christopher Benner; Bilal E Kerman; David Gosselin; Clotilde Lagier-Tourenne; Chiara Zuccato; Elena Cattaneo; Fred H Gage; Don W Cleveland; Christopher K Glass
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

6.  Neuroprotective role of the basic leucine zipper transcription factor NFIL3 in models of amyotrophic lateral sclerosis.

Authors:  So-ichi Tamai; Keisuke Imaizumi; Nobuhiro Kurabayashi; Minh Dang Nguyen; Takaya Abe; Masatoshi Inoue; Yoshitaka Fukada; Kamon Sanada
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

Review 7.  NADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: a bipartisan affair?

Authors:  Evan A Bordt; Brian M Polster
Journal:  Free Radic Biol Med       Date:  2014-08-01       Impact factor: 7.376

8.  Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS.

Authors:  Hong Z Yin; Darryl T Tang; John H Weiss
Journal:  Exp Neurol       Date:  2007-07-24       Impact factor: 5.330

9.  Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis.

Authors:  Marcelo R Vargas; Delinda A Johnson; Daniel W Sirkis; Albee Messing; Jeffrey A Johnson
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

Review 10.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.